AstraZeneca opens new US$1B R&D facility in Massachusetts

USA—AstraZeneca has opened a new global research and development (R&D) facility in Cambridge, Massachusetts, as part of an investment exceeding US$ 1 billion in the state to expand its drug discovery capabilities and strengthen its US research operations.

The 18-storey building at 290 Binney Street covers 570,000 square feet and houses ten floors of interconnected laboratories.

The facility features continuous automation, robotics and agentic artificial intelligence (AI), technologies designed to support research workflows and improve laboratory efficiency.

Located in Kendall Square, a major biotechnology and life sciences hub, the new centre will operate alongside AstraZeneca’s genomic medicine facility at 100 Binney Street.

Together, the two sites will accommodate approximately 2,000 researchers and scientists, while the expansion is expected to increase the company’s Massachusetts workforce by more than 50% in the coming years.

Research focus spans major disease areas

Research teams at the new centre will investigate treatments across several therapeutic areas, including breast cancer, chronic obstructive pulmonary disease (COPD), metabolic diseases, obesity, oncology and rare conditions.

The facility will also support research into biologics and cell therapies, broadening the company’s capabilities across different treatment platforms.

The combination of specialised laboratories, automation and AI reflects the growing role of advanced technologies in pharmaceutical research.

Automated systems can help researchers manage repetitive laboratory processes and generate data more consistently, while AI tools may support the analysis of complex biological information.

Their practical value will depend on how effectively these technologies integrate with research teams and existing drug development processes.

AstraZeneca Chief Executive Officer Pascal Soriot said Kendall Square was an important innovation ecosystem and a key location for the company’s scientific research.

He added that the new centre reflected AstraZeneca’s long-term commitment to Massachusetts and its ambition to develop innovations in the United States for patients worldwide.

Part of a wider US investment programme

The Massachusetts expansion forms part of AstraZeneca’s broader US$50 billion investment programme in the United States.

The company has operated in Massachusetts for more than 75 years and currently employs over 25,000 people across 24 corporate, commercial, manufacturing and research sites nationwide.

Its activities also support nearly 100,000 jobs across the US economy.

The investment comes as pharmaceutical companies expand research infrastructure and adopt technologies intended to accelerate the identification and development of new treatments.

For AstraZeneca, increasing laboratory capacity in Kendall Square strengthens its presence in a region where biotechnology companies, academic institutions and research organisations operate within a concentrated life sciences ecosystem.

The new facility also expands AstraZeneca’s global research network, which spans more than 40 countries.

Its other principal strategic R&D centre in the United States is located in Gaithersburg, Maryland.

Broader oncology research collaborations

Alongside its investment in research infrastructure, AstraZeneca continues to pursue external collaborations to advance its drug development pipeline.

The company and Daiichi Sankyo have partnered with Summit Therapeutics to explore their co-developed antibody-drug conjugate, Datroway (datopotamab deruxtecan), as well as ivonescimab, a candidate licensed by Summit.

Antibody-drug conjugates combine targeted antibodies with cancer-killing agents to deliver treatment to specific cells.

Research into these therapies forms part of the pharmaceutical industry’s broader effort to develop more targeted cancer treatments and expand options for patients with difficult-to-treat malignancies.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on LinkedIn for updates.